论文部分内容阅读
肾母细胞瘤是儿童时期最常见的肾脏实体恶性肿瘤,随着以手术为主的综合治疗的不断发展,肾母细胞瘤术后无瘤生存率有了显著提高,而术前化疗在其中起了举足轻重的作用。目前长春新碱、放线菌素D及表柔比星是术前化疗的基础药物。术前化疗有不同的给药途径及方法,各种方法又有不同的化疗方案,其使肿瘤缩小增加肿瘤全瘤切除率和预测肾母细胞瘤患者预后方面的作用得到了越来越广泛的认可。未来术前化疗的目标将是提高化疗有效性,降低化疗药物近期、远期毒性。
Malignant nephroblastoma is the most common renal solid malignant tumor in childhood. With the continuous development of surgery-based comprehensive treatment, the postoperative tumor-free survival rate of nephroblastoma has been significantly increased, while the preoperative chemotherapy in which The pivotal role. Currently vincristine, actinomycin D and epirubicin are the basis of preoperative chemotherapy drugs. Preoperative chemotherapy has different routes of administration and methods, various methods have different chemotherapy regimens, which make the tumor shrinkage increase the rate of tumor total tumor resection and predict the prognosis of nephroblastoma patients have been more and more widely Recognized. The goal of future preoperative chemotherapy will be to improve the effectiveness of chemotherapy and reduce the short-term and long-term toxicity of chemotherapy drugs.